# HLA-DR $\alpha$ siRNA (h): sc-37113



The Power to Question

## **BACKGROUND**

Major histocompatibility complex (MHC) class II molecules destined for presentation to CD4+ helper T cells is determined by two key events. These events include the dissociation of class II-associated invariant chain peptides (CLIP) from an antigen binding groove in mhc ii- $\alpha/\beta$  dimers through the activity of MHC molecules HLA-DM and -DO, and subsequent peptide antigen binding. Accumulating in endosomal/lysosomal compartments and on the surface of B cells, HLA-DM, -DO molecules regulate the dissociation of CLIP and the subsequent binding of exogenous peptides to HLA class II molecules (HLA-DR, -DQ and -DP) by sustaining a conformation that favors peptide exchange. RFLP analysis of HLA-DM genes from rheumatoid arthritis (RA) patients suggests that certain polymorphisms are genetic factors for RA susceptibility. HLA-B belongs to the HLA class I heavy chain paralogs. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen. HLA-B and -C can form heterodimers consisting of a membrane anchored heavy chain and a light chain (β-2-Microglobulin). Polymorphisms yield hundreds of HLA-B and -C alleles.

# **REFERENCES**

- Horejsi, V., et al. 1986. Characterization of seven new monoclonal antibodies against human DR, DR + DP and DQ1 + DQ3 antigens. Tissue Antigens 28: 288-297.
- 2. Horejsi, V., et al. 1986. Monoclonal antibodies against human leucocyte antigens. I. Antibodies against  $\beta$ -2-Microglobulin, immunoglobulin  $\kappa$  light chains, HLA-DR-like antigens, T8 antigen, T1 antigen, a monocyte antigen, and a pan-leucocyte antigen. Folia Biol. 32: 12-25.

# OSOMAL LOCATION

Genetic locus: HLA-DRA (human) mapping to 6p21.32.

## **PRODUCT**

HLA-DR $\alpha$  siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10  $\mu$ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see HLA-DR $\alpha$  shRNA Plasmid (h): sc-37113-SH and HLA-DR $\alpha$  shRNA (h) Lentiviral Particles: sc-37113-V as alternate gene silencing products.

For independent verification of HLA-DR $\alpha$  (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-37113A, sc-37113B and sc-37113C.

## STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330  $\mu$ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330  $\mu$ l of RNAse-free water makes a 10  $\mu$ M solution in a 10  $\mu$ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

#### **APPLICATIONS**

HLA-DR $\alpha$  siRNA (h) is recommended for the inhibition of HLA-DR $\alpha$  expression in human cells.

# **SUPPORT REAGENTS**

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 µM in 66 µl. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

## **GENE EXPRESSION MONITORING**

HLA-DR $\alpha$  (G-7): sc-55593 is recommended as a control antibody for monitoring of HLA-DR $\alpha$  gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG $\kappa$  BP-HRP: sc-516102 or m-lgG $\kappa$  BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker<sup>TM</sup> Molecular Weight Standards: sc-2035, UltraCruz<sup>®</sup> Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-lgG $\kappa$  BP-FITC: sc-516140 or m-lgG $\kappa$  BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz<sup>®</sup> Mounting Medium: sc-24941 or UltraCruz<sup>®</sup> Hard-set Mounting Medium: sc-359850.

# **RT-PCR REAGENTS**

Semi-quantitative RT-PCR may be performed to monitor HLA-DR $\alpha$  gene expression knockdown using RT-PCR Primer: HLA-DR $\alpha$  (h)-PR: sc-37113-PR (20 µl, 541 bp). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

## **SELECT PRODUCT CITATIONS**

- Jang, I.K., et al. 2014. B7-H1 inhibits T cell proliferation through MHC class II in human mesenchymal stem cells. Transplant. Proc. 46: 1638-1641.
- Zhang, X., et al. 2016. Positive feedback cycle of TNFα promotes staphylococcal enterotoxin B-induced THP-1 cell apoptosis. Front. Cell. Infect. Microbiol. 6: 109.
- 3. Gilardini Montani, M.S., et al. 2018. EBV up-regulates PD-L1 on the surface of primary monocytes by increasing ROS and activating TLR signaling and Stat3. J. Leukoc. Biol. 104: 821-832.
- Orlik, C., et al. 2019. Keratinocytes costimulate naive human T cells via CD2: a potential target to prevent the development of proinflammatory Th1 cells in the skin. Cell. Mol. Immunol. 17: 380-394.

# **RESEARCH USE**

For research use only, not for use in diagnostic procedures.